# Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC

> **NCT06173505** · PHASE1,PHASE2 · TERMINATED · sponsor: **Xencor, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Nonsquamous Non-small Cell Lung Cancer

## Interventions

- **COMBINATION_PRODUCT:** Vudalimab + Carboplatin + Pemetrexed
- **COMBINATION_PRODUCT:** Pembrolizumab + Carboplatin + Pemetrexed

## Key facts

- **NCT ID:** NCT06173505
- **Lead sponsor:** Xencor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-12-27
- **Primary completion:** 2025-12-24
- **Final completion:** 2025-12-29
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06173505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06173505, "Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06173505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*